— ORR of 72% Observed in Patients with >2L HER2 Positive Gastric or Gastroesophageal Junction Cancer
— Estimated OS at 12 months of 76%
— ALX Oncology to Host Conference Call on July 6th at 8:30 a.m. ET
— ORR of 72% Observed in Patients with >2L HER2 Positive Gastric or Gastroesophageal Junction Cancer
— Estimated OS at 12 months of 76%
— ALX Oncology to Host Conference Call on July 6th at 8:30 a.m. ET